ORG Wealth Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, HoldingsChannel reports. The fund purchased 1,339 shares of the company’s stock, valued at approximately $1,187,000. Eli Lilly and Company comprises approximately 0.4% of ORG Wealth Partners LLC’s holdings, making the stock its 21st largest position.
A number of other hedge funds also recently modified their holdings of the business. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the second quarter valued at $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Morton Brown Family Wealth LLC raised its holdings in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Richardson Financial Services Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $43,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the subject of several analyst reports. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $979.29.
Eli Lilly and Company Stock Up 0.5 %
NYSE LLY opened at $936.61 on Monday. The stock has a market capitalization of $890.16 billion, a P/E ratio of 137.27, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. The stock has a fifty day moving average of $910.84 and a 200-day moving average of $853.38.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Best Stocks Under $5.00
- Hewlett Packard Enterprises: 4 Reasons to Get In Now on the Stock
- Want to Profit on the Downtrend? Downtrends, Explained.
- Chicken or Egg? Does Tyson Have More Upside Than Cal-Maine Stock?
- What is a SEC Filing?
- Delta Air Lines: 3 Reasons This Dip Is Too Good to Miss
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.